Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors

Journal of Virology

Volumn 72, Issue 7, 1998, Pages 6146-6150

  Doyon, Louise ^a   Payant, Catherine ^b   Brakier Gingras, Léa ^b   Lamarre, Daniel ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; POL PROTEIN; PROTEINASE INHIBITOR;

ARTICLE; DRUG SENSITIVITY; FRAMESHIFT MUTATION; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINASE INHIBITION; RIBOSOMAL FRAMESHIFTING; SEQUENCE ANALYSIS; STRUCTURE ACTIVITY RELATION;

EID: 0031748806     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.7.6146-6150.1998     Document Type: Article

References (25)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Brierly, I., and A. J. Jenner. 1992. Mutational analysis of the "slippery-sequence" component of a coronavirus ribosomal frameshifting signal. J. Mol. Biol. 227:463-479.
3. Carrillo, A., H. Sham, D. Norbeck, D. Kempf, W. Kohlbrenner, J. Plattner, J. Leonard, and A. Molla. 1997. Selection and analysis of HIV-1 variants with increased resistance to ABT-378, a novel protease inhibitor, abstr. 462. In Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections 1997. Infectious Diseases Society of America, Washington. D.C.
4. Chamorro, M., N. Parkin, and H. E. Varmus. 1992. An RNA pseudoknot and an optimal heptameric shift site are required for highly efficient ribosomal frameshifting on a retroviral messenger RNA. Proc. Natl. Acad. Sci. USA 89:713-717.
5. Croteau, G., L. Doyon, D. Thibeault, G. McKercher, L. Pilote, and D. Lamarre. 1997. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J. Virol. 71:1089-1096.
6. Doyon, L., G. Croteau, D. Thibeault, F. Poulin, L. Pilote, and D. Lamarre. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70:3763-3769.
7. Farabaugh, P. J. 1993. Alternative readings of the genetic code. Cell 74:591-596.
8. Farabaugh, P. J. 1996. Programmed translational frameshifting. Annu. Rev. Genet. 30:507-528.
9. Gesteland, R. F., and J. F. Atkins. 1996. Recoding: dynamic reprogramming of translation. Annu. Rev. Biochem. 65:741-768.
10. Gulnik, S. V., L. I. Suvorov, B. Liu, B. Yu, B. Anderson, H. Mitsuya, and J. W. Erickson. 1995. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34: 9282-9287.
11. Higuchi, R., B. Krummel, and R. K. Saiki. 1988. A general method of in vitro preparation and specific mutagcnesis of DNA fragments: study of protein and DNA interaction. Nucleic Acids Res. 16:7351-7367.
12. Hunter, E. 1994. Macromolecular interactions in the assembly of HIV and other retroviruses. Semin. Virol. 5:71-83.
13. Jacks, T., M. D. Power, F. R. Masiarz, P. A. Luciw, P. J. Barr, and H. E. Varmus. 1988. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 331:280-283.
14. Jacks, T., H. D. Madhani, F. R. Masiarz, and H. E. Varmus. 1988. Signals for ribosomal frameshifting in the Rous sarcoma virus gag-pol region. Cell 55:447-458.
15. Lamarre, D., G. Croteau, E. Wardrop, L. Bourgon, D. Thibeault, C. Clouette, M. Vaillancourt, E. Cohen, C. Pargellis, C. Yoakim, and P. C. Anderson. 1997. Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 41:965-971.
16. Larsen, B., N. M. Wills, R. F. Gesteland, and J. F. Atkins. 1994. rRNA-mRNA base pairing stimulates a programmed -1 ribosomal frameshift. J. Bacteriol. 176:6842-6851.
17. Myers, G., B. Korber, B. Foley, K. T. Jeang, J. W. Mellors, and S. Wain-Hobson. 1996. Human retroviruses and AIDS: a compilation and analysis of nucleic acid and amino acid sequences. Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, N.Mex.
18. Park, J., and C. D. Morrow. 1991. Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production. J. Virol. 65:5111-5117.
19. Parkin, N. T., M. Chamorro, and H. E. Varmus. 1992. Human immunodeficiency virus type 1 gag-pol frameshifting is dependent on downstream mRNA secondary structure: demonstration by expression in vivo. J. Virol. 66:5147-5151.
20. Pazhanisamy, S., M. Stuver, A. B. Cullinan, N. Margolin, B. G. Rao, and D. J. Livingston. 1996. Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants. J. Biol. Chem. 271:17979-17985.
21. Schinazi, R. F., B. A. Larder, and J. W. F. Mellors. 1997. Mutations in retroviral genes associated with drug resistance. Int. Antivir. News 5:129-142.
22. Seed, B., and J. Y. Sheen. 1988. A simple phase-extraction assay for chloramphenicol acetyletransferase activity. Gene 67:271-277.
23. Veronese, F., R. Rahman, T. D. Copeland, S. Oroszlan, R. C. Gallo, and M. G. Sarngadharan. 1987. Immunological and chemical analysis of p6, the carboxyl-terminal fragment of HIV p15. AIDS Res. Hum. Retroviruses 3:253-264.
24. Wilson, W., M. Braddock, S. E. Adams, P. D. Rathjen, S. M. Kingsman, and A. J. Kingsman. 1988. HIV expression strategies: ribosomal frameshifting is directed by a short sequence in both mammalian and yeast systems. Cell 55:1159-1169.
25. Zhang, Y.-M., H. Imamichi, T. Imamichi, H. C. Lane, J. Falloon, M. B. Vasudevachari, and N. P. Salzman. 1997. Drug resistance during Indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71:6662-6670.